Oncolytics Biotech (ONCY) Beginning Cash Balance (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Beginning Cash Balance data on file, last reported at $11.1 million in Q1 2025.

• On a quarterly basis, Beginning Cash Balance fell 57.12% year-over-year to $11.1 million in Q1 2025; TTM through Sep 2025 was $11.1 million, a 57.12% decrease from a year earlier, with the FY2024 full-year figure at $25.5 million, up 194.92% from the prior year.
• Beginning Cash Balance for Q1 2025 stood at $11.1 million, down from $25.9 million in the prior quarter.
• Over the last five years, Beginning Cash Balance for ONCY reached as high as $41.0 million in Q2 2021 and fell as low as $337.96 in Q4 2021.
• Historically, Beginning Cash Balance has averaged $23.9 million across 5 years, with a median of $25.9 million in 2024.
• Across the five-year window, Beginning Cash Balance soared 2198.08% in 2021 and tumbled 73.51% in 2023, its largest moves.
• Year by year, Beginning Cash Balance stood at $337.96 in 2021, then soared by 9163124.05% to $31.0 million in 2022, then plunged by 72.13% to $8.6 million in 2023, then soared by 200.24% to $25.9 million in 2024, then plunged by 57.12% to $11.1 million in 2025.
• Per Business Quant data, the three most recent Beginning Cash Balance figures were $11.1 million in Q1 2025, $25.9 million in Q1 2024, and $8.6 million in Q1 2023.